Reports Q1 revenue $2.46B, consensus $2.34B. President and CEO Christopher Viehbacher said: "In the first quarter, we continued to make strong progress against our business priorities, most importantly execution of three potential launches in 2023. Biogen is at the forefront of groundbreaking science as demonstrated by our ability to help advance new surrogate biomarkers in Alzheimer’s disease and ALS while also delivering breakthrough data to address tau pathology in Alzheimer’s. I believe these achievements represent Biogen at its best. We also continue to remain diligent in prioritizing our R&D pipeline, optimizing our operating model, and evaluating external opportunities as we work to establish a sustainable growth trajectory."
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
- Biogen price target raised to $300 from $295 at BofA
- Agios Pharmaceuticals appoints Capello to board of directors
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Biogen price target raised to $320 from $315 at Argus
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue